However, PKC inhibitors have proved unsuccessful as anti-cancer agents in clinical trials [4, 32] and recent evidence has come to the fore suggesting that PKCs can play a tumour suppressor role in cancer [7–9]. The gene discussed is PRRT2; the disease is cancer.